+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Chronic Traumatic Encephalopathy Drug"

From
Chronic Traumatic Encephalopathy - Pipeline Insight, 2021 - Product Thumbnail Image

Chronic Traumatic Encephalopathy - Pipeline Insight, 2021

  • Clinical Trials
  • February 2021
  • 60 Pages
  • Global
From
Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018 - Product Thumbnail Image

Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018

  • Drug Pipelines
  • August 2018
  • 30 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Chronic Traumatic Encephalopathy (CTE) is a degenerative brain disorder caused by repeated head trauma. It is a form of dementia that can lead to memory loss, confusion, impaired judgment, aggression, depression, and progressive dementia. CTE is most commonly found in athletes who have experienced repeated head trauma, such as football players, boxers, and hockey players. As a result, the CTE drug market is focused on developing treatments to reduce the risk of CTE and improve the quality of life for those affected. The CTE drug market is part of the larger Central Nervous System (CNS) drug market, which includes treatments for neurological and psychiatric disorders. CNS drugs are used to treat a wide range of conditions, including Alzheimer’s disease, Parkinson’s disease, depression, anxiety, and schizophrenia. Some companies in the CTE drug market include Biogen, AbbVie, Merck, and Pfizer. These companies are researching and developing treatments for CTE, including drugs, therapies, and lifestyle modifications. Additionally, there are several smaller companies that are researching and developing treatments for CTE, such as Axon Neuroscience, BrainStorm Cell Therapeutics, and Neurotrope. Show Less Read more